PT-141 (Bremelanotide): What It Does, Who It's Approved For, and What It Costs

PT-141 is one of the few molecules where the marketing and the medicine have almost completely separated. As bremelanotide, it is a prescription drug with an FDA approval, a licensed manufacturer and a defined population. As PT-141, it is sold in vials by peptide retailers to anyone with a card, marked "for research use only" to sidestep the regulation the prescription version had to satisfy. They are the same molecule and they are not the same product.

What bremelanotide actually is

Bremelanotide is a synthetic peptide that activates melanocortin receptors in the brain, principally MC4R. That mechanism is what makes it unusual. Sildenafil and its relatives work on blood flow to genital tissue — they help the plumbing respond once desire exists. Bremelanotide acts upstream, on the neural pathways involved in sexual motivation itself. It descends from melanotan II, a tanning peptide, whose researchers noticed an unexpected effect on arousal.

It is given as a subcutaneous injection from a single-use autoinjector into the thigh or abdomen, at least 45 minutes before anticipated sexual activity. It is not taken daily. The label caps use at one dose in 24 hours and eight doses a month, which is worth understanding before assuming it is an everyday option.

Who it is approved for — and who it is not

The FDA approved Vyleesi in June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Each of those words narrows it. "Acquired" means desire that was previously present and fell away, not lifelong low desire. "Generalised" means it applies across situations and partners rather than to one relationship. And "premenopausal" is the boundary that matters most for readers of this site.

The approval stops at menopause because the postmenopausal evidence did not support extending it. That is not the same as evidence of harm — it is an absence of demonstrated benefit in that group. Some clinicians prescribe it off-label after menopause; that is a legitimate conversation to have, but it should be framed honestly as off-label use rather than as an approved treatment.

It is contraindicated in uncontrolled high blood pressure and in known cardiovascular disease, because it raises blood pressure transiently after each dose.

What the trials actually showed

Approval rested on two identical phase 3 trials, RECONNECT, running 24 weeks in about 1,200 premenopausal women. Both met their co-primary endpoints, and both did so by margins smaller than the marketing implies.

The desire score

Desire was measured on the Female Sexual Function Index desire domain, which runs from 1.2 to 6.0. Bremelanotide improved it by roughly 0.30 points more than placebo. Placebo itself improved desire substantially — a consistent finding in sexual-function trials and a reason to be sceptical of any before-and-after story without a control arm.

The distress score

The second endpoint measured distress about low desire, and it also improved more than placebo. This matters because the diagnosis requires distress: low desire without personal distress is not a disorder, and that distinction keeps the drug from being pointed at women whose desire is simply lower than someone else thinks it should be.

What did not change

Neither trial showed a significant increase in the number of satisfying sexual events. That is the endpoint most people assume they are buying, and it did not move. The honest summary is that bremelanotide shifted how women rated desire and distress, without changing how often sex happened.

Side effects, in the order you will meet them

Nausea

The dominant one. Around 40% of trial participants experienced it, most commonly with the first dose, and 18% took an anti-nausea medicine for it. About 8% stopped the drug because of it. Nausea usually lessens with subsequent doses, but the first injection is the one to plan around.

Flushing and injection-site reactions

Flushing affected roughly a fifth of participants. Local redness or bruising at the injection site is common and self-limiting.

Blood pressure

Each dose transiently raises blood pressure and lowers heart rate, peaking within the first hour. In healthy participants this is small and resolves within 12 hours. In uncontrolled hypertension or established cardiovascular disease it is the reason the drug is contraindicated.

Darkening of the skin

Focal hyperpigmentation — on the face, gums or breasts — occurred in about 1% of participants and did not always resolve after stopping. It is more likely with more frequent dosing and in people with darker skin, which is part of why the monthly cap exists.

PT-141 sold online is not Vyleesi

This is the part that the search results bury. Vials labelled PT-141 are marketed by peptide retailers under a "research use only" designation, which is a regulatory posture rather than a quality standard. Nothing verifies the identity of the powder, the stated quantity, the sterility of the vial, or what else is in it. Buyers reconstitute it themselves and dose by their own arithmetic.

The known risks are not hypothetical. Melanotan II, bremelanotide's structural relative sold the same way, has documented case reports of changes in moles and of melanoma diagnosed after use — a plausible concern for any melanocortin agonist obtained without medical oversight. The approved product exists precisely so that dose, purity and monitoring are not left to the buyer.

Cost and access

Vyleesi is a specialty product and insurance coverage for desire drugs is inconsistent — many plans exclude them as lifestyle medications. The manufacturer runs a savings programme, and telehealth services prescribe it after an assessment. Grey-market vials are far cheaper, and that price gap is the entire reason the unregulated market exists. What it buys is an unverified powder and no clinician watching your blood pressure or your skin.

What to consider before any desire drug

Low desire at midlife is rarely a single-cause problem, and the most common reversible causes are not treated by a desire drug at all.

• Pain. If sex hurts because of vaginal dryness, desire falls in response. Treating the dryness with a regular moisturizer or local estrogen restores more than any drug aimed at desire.
• Medication. SSRIs are the commonest pharmacological cause of low desire, and dose changes or switching are options worth exploring first.
• Sleep and mood. The exhaustion of fragmented sleep suppresses desire reliably, and treating night sweats often lifts it without touching desire directly.
• Testosterone. For postmenopausal women with distressing low desire, testosterone has better evidence than bremelanotide does in that group, though it is prescribed off-label in most countries and needs monitoring.

Our guide to low libido in menopause works through these in order.

How it compares with the other options for low desire

Three drugs are used for low sexual desire in women, and they work in genuinely different ways. None of them is a strong treatment, which is the honest frame for the whole category.

The practical distinction is timing and tolerance. Flibanserin has to be taken nightly and interacts with alcohol, which rules it out for many people. Bremelanotide is used only when wanted, but the first dose brings a real chance of nausea. Testosterone is the only one with meaningful postmenopausal evidence and the only one you cannot get on label. Our comparison of hormonal and non-hormonal options covers the wider decision.

What a reasonable trial of it looks like

If you and a clinician decide to try it, a few things make the attempt informative rather than inconclusive.

• Rule out the reversible causes first. Pain, medication and sleep account for most low desire at midlife, and none of them respond to a desire drug.
• Plan the first dose. Nausea is worst on dose one. Trying it on an evening with no expectations attached, rather than on an occasion that matters, makes the side effect easier to judge.
• Decide in advance what success means. The trials moved desire and distress scores, not the frequency of satisfying sex. If the second is your goal, say so before you start.
• Give it several uses. Nausea usually lessens after the first dose, so one bad experience is not a complete test.
• Watch your skin. New darkening on the face, gums or breasts is a reason to stop and speak to your prescriber, because it does not always reverse.